mToR	mtor	O	O	O	O
inhibitors-induced	inhibitors-induced	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
:	:	O	O	O	O
mechanisms	mechanisms	O	O	O	O
,	,	O	O	O	O
significance	significance	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
management	management	O	O	O	O
.	.	O	O	O	O

Massive	massive	O	O	O	O
urinary	urinary	O	O	O	O
protein	protein	O	O	OTHERS	I
excretion	excretion	O	O	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
observed	observed	O	O	O	O
after	after	O	O	O	O
conversion	conversion	O	O	O	O
from	from	O	O	O	O
calcineurin	calcineurin	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
mammalian	mammalian	O	O	O	O
target	target	O	O	O	O
of	of	O	O	O	O
rapamycin	rapamycin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
mToR	mtor	O	O	O	O
)	)	O	O	O	O
inhibitors	inhibitors	O	O	O	O
,	,	O	O	O	O
especially	especially	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
in	in	O	O	O	O
renal	renal	O	O	O	O
transplant	transplant	O	O	O	O
recipients	recipients	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	O	OTHERS	I
allograft	allograft	O	O	OTHERS	I
nephropathy	nephropathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Because	because	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
predictive	predictive	O	O	O	O
factor	factor	O	O	O	O
of	of	O	O	O	O
poor	poor	O	O	O	O
transplantation	transplantation	O	O	O	O
outcome	outcome	O	O	O	O
,	,	O	O	O	O
many	many	O	O	O	O
studies	studies	O	O	O	O
focused	focused	O	O	O	O
on	on	O	O	O	O
this	this	O	O	O	O
adverse	adverse	O	O	O	O
event	event	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
past	past	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

Whether	whether	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
was	was	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
only	only	O	O	O	O
a	a	O	O	O	O
consequence	consequence	O	O	O	O
of	of	O	O	O	O
calcineurin	calcineurin	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
withdrawal	withdrawal	O	O	O	O
remained	remained	O	O	O	O
unsolved	unsolved	O	O	O	O
until	until	O	O	O	O
high	high	O	O	O	O
range	range	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
observed	observed	O	O	O	O
during	during	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
in	in	O	O	O	O
islet	islet	O	O	O	O
transplantation	transplantation	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
de	de	O	O	O	O
novo	novo	O	O	O	O
.	.	O	O	O	O

Podocyte	podocyte	O	O	O	O
injury	injury	O	O	O	O
and	and	O	O	O	O
focal	focal	O	O	OTHERS	I
segmental	segmental	O	DISEASE	OTHERS	I
glomerulosclerosis	glomerulosclerosis	O	DISEASE	OTHERS	I
have	have	O	O	O	O
been	been	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
mToR	mtor	O	O	O	O
inhibition	inhibition	O	O	O	O
in	in	O	O	O	O
some	some	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
the	the	O	O	O	O
pathways	pathways	O	O	O	O
underlying	underlying	O	O	O	O
these	these	O	O	O	O
lesions	lesions	O	O	O	O
remain	remain	O	O	O	O
hypothetic	hypothetic	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
discuss	discuss	O	O	O	O
herein	herein	O	O	O	O
the	the	O	O	O	O
possible	possible	O	O	O	O
mechanisms	mechanisms	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
significance	significance	O	O	O	O
of	of	O	O	O	O
mToR	mtor	O	O	O	O
blockade-induced	blockade-induced	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
.	.	O	O	O	O

